The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Faslodex     (7R,8S,9S,13S,14S,17S)-13- methyl-7-[9-(4,4...

Synonyms: Fulvestrant, Faslodex (TN), CHEMBL1358, PubChem24291, S1191_Selleck, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Faslodex


Psychiatry related information on Faslodex


High impact information on Faslodex


Chemical compound and disease context of Faslodex


Biological context of Faslodex


Anatomical context of Faslodex


Associations of Faslodex with other chemical compounds


Gene context of Faslodex


Analytical, diagnostic and therapeutic context of Faslodex


  1. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Howell, A., DeFriend, D., Robertson, J., Blamey, R., Walton, P. Lancet (1995) [Pubmed]
  2. Regulation of avian osteoclastic H+ -ATPase and bone resorption by tamoxifen and calmodulin antagonists. Effects independent of steroid receptors. Williams, J.P., Blair, H.C., McKenna, M.A., Jordan, S.E., McDonald, J.M. J. Biol. Chem. (1996) [Pubmed]
  3. Estrogen regulation of intestinal calcium absorption in the intact and ovariectomized adult rat. Ten Bolscher, M., Netelenbos, J.C., Barto, R., Van Buuren, L.M., Van der vijgh, W.J. J. Bone Miner. Res. (1999) [Pubmed]
  4. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Watts, C.K., Brady, A., Sarcevic, B., deFazio, A., Musgrove, E.A., Sutherland, R.L. Mol. Endocrinol. (1995) [Pubmed]
  5. Estrogen represses whereas the estrogen-antagonist ICI 182780 stimulates placental CRH gene expression. Ni, X., Nicholson, R.C., King, B.R., Chan, E.C., Read, M.A., Smith, R. J. Clin. Endocrinol. Metab. (2002) [Pubmed]
  6. A new estrogen receptor antagonist--an overview of available data. Jones, S.E. Breast Cancer Res. Treat. (2002) [Pubmed]
  7. The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis. Hur, J., Chesnes, J., Coser, K.R., Lee, R.S., Geck, P., Isselbacher, K.J., Shioda, T. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  8. 3-Methylcholanthrene and other aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha. Abdelrahim, M., Ariazi, E., Kim, K., Khan, S., Barhoumi, R., Burghardt, R., Liu, S., Hill, D., Finnell, R., Wlodarczyk, B., Jordan, V.C., Safe, S. Cancer Res. (2006) [Pubmed]
  9. Mechanisms of Tumor Regression and Resistance to Estrogen Deprivation and Fulvestrant in a Model of Estrogen Receptor-Positive, HER-2/neu-Positive Breast Cancer. Massarweh, S., Osborne, C.K., Jiang, S., Wakeling, A.E., Rimawi, M., Mohsin, S.K., Hilsenbeck, S., Schiff, R. Cancer Res. (2006) [Pubmed]
  10. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Fan, M., Yan, P.S., Hartman-Frey, C., Chen, L., Paik, H., Oyer, S.L., Salisbury, J.D., Cheng, A.S., Li, L., Abbosh, P.H., Huang, T.H., Nephew, K.P. Cancer Res. (2006) [Pubmed]
  11. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Robertson, J.F., Nicholson, R.I., Bundred, N.J., Anderson, E., Rayter, Z., Dowsett, M., Fox, J.N., Gee, J.M., Webster, A., Wakeling, A.E., Morris, C., Dixon, M. Cancer Res. (2001) [Pubmed]
  12. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. Osborne, C.K., Pippen, J., Jones, S.E., Parker, L.M., Ellis, M., Come, S., Gertler, S.Z., May, J.T., Burton, G., Dimery, I., Webster, A., Morris, C., Elledge, R., Buzdar, A. J. Clin. Oncol. (2002) [Pubmed]
  13. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Jelovac, D., Macedo, L., Goloubeva, O.G., Handratta, V., Brodie, A.M. Cancer Res. (2005) [Pubmed]
  14. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines. Müller, V., Jensen, E.V., Knabbe, C. Cancer Res. (1998) [Pubmed]
  15. Ligand-Selective Interdomain Conformations of Estrogen Receptor-{alpha}. Padron, A., Li, L., Kofoed, E.M., Schaufele, F. Mol. Endocrinol. (2007) [Pubmed]
  16. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. DeFriend, D.J., Howell, A., Nicholson, R.I., Anderson, E., Dowsett, M., Mansel, R.E., Blamey, R.W., Bundred, N.J., Robertson, J.F., Saunders, C. Cancer Res. (1994) [Pubmed]
  17. interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant). Bouker, K.B., Skaar, T.C., Fernandez, D.R., O'Brien, K.A., Riggins, R.B., Cao, D., Clarke, R. Cancer Res. (2004) [Pubmed]
  18. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B. Wu, J., Richer, J., Horwitz, K.B., Hyder, S.M. Cancer Res. (2004) [Pubmed]
  19. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Sabnis, G.J., Jelovac, D., Long, B., Brodie, A. Cancer Res. (2005) [Pubmed]
  20. Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Huynh, H.T., Pollak, M. Cancer Res. (1993) [Pubmed]
  21. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha. Long, X., Nephew, K.P. J. Biol. Chem. (2006) [Pubmed]
  22. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Newman, S.P., Bates, N.P., Vernimmen, D., Parker, M.G., Hurst, H.C. Oncogene (2000) [Pubmed]
  23. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Howell, A., Robertson, J.F., Quaresma Albano, J., Aschermannova, A., Mauriac, L., Kleeberg, U.R., Vergote, I., Erikstein, B., Webster, A., Morris, C. J. Clin. Oncol. (2002) [Pubmed]
  24. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Stabile, L.P., Lyker, J.S., Gubish, C.T., Zhang, W., Grandis, J.R., Siegfried, J.M. Cancer Res. (2005) [Pubmed]
  25. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Hershberger, P.A., Vasquez, A.C., Kanterewicz, B., Land, S., Siegfried, J.M., Nichols, M. Cancer Res. (2005) [Pubmed]
  26. Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response. Ishii, Y., Papa, L., Bahadur, U., Yue, Z., Aguirre-Ghiso, J., Shioda, T., Waxman, S., Germain, D. Clin. Cancer Res. (2011) [Pubmed]
  27. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors. Thottassery, J.V., Sun, Y., Westbrook, L., Rentz, S.S., Manuvakhova, M., Qu, Z., Samuel, S., Upshaw, R., Cunningham, A., Kern, F.G. Cancer Res. (2004) [Pubmed]
  28. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. Carroll, J.S., Prall, O.W., Musgrove, E.A., Sutherland, R.L. J. Biol. Chem. (2000) [Pubmed]
  29. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells. Bindels, E.M., Lallemand, F., Balkenende, A., Verwoerd, D., Michalides, R. Oncogene (2002) [Pubmed]
  30. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. McKeage, K., Curran, M.P., Plosker, G.L. Drugs (2004) [Pubmed]
WikiGenes - Universities